


Innovations powered by **XBIO**™ technology

Next Science Limited Investor Presentation

28 February 2020



NEXT SCIENCE®

Approved by the Board of Next Science Limited

Disclaimers (HWL)

This presentation has been prepared by Next Science Limited ACN 622 382 549 (**Next Science**), based on information available as at the date of this presentation, and is provided for general information purposes only. No party other than Next Science has authorised or caused the issue of this document, or takes responsibility for, or makes any statements, representations or undertakings in this presentation.

This presentation is provided in summary form and is not intended to be relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial situation or needs of any particular investor. To the maximum extent permitted by law, Next Science and each of its shareholders, directors, officers, agents, employees or advisers, and any of their respective affiliates or related bodies corporate, make no warranty or representation (express or implied) as to the accuracy, reliability, timeliness or completeness of the information contained in this presentation. Specifically, several matters referred to in the presentation remain under investigation and are subject to change or even elimination, depending on further research and investigation. Further, any opinions (including any forward looking statements) expressed in this presentation are subject to change without notice.

This presentation is not a prospectus, product disclosure statement, pathfinder document or any other type of public offer disclosure document for the purposes of the *Corporations Act 2001 (Cth)* (**Corporations Act**) and has not been, and is not required to be, lodged with the Australian Securities and Investments Commission. This presentation is not intended to constitute legal, tax, accounting or other advice and does not take into account any individual's investment objectives, taxation situation, financial situation or needs, nor is it a recommendation to acquire any entitlements or securities in Next Science.

This presentation may include forward-looking statements, including statements about Next Science's financial results, guidance and/or business prospects that may involve risks or uncertainties and may involve significant items of subjective judgement and assumptions of future events that may or may not eventuate. Forward looking statements can generally be identified by the use of forward looking words such as "anticipate", "likely", "expect", "intend", "should", "could", "may", "propose", "will", "believe", "forecast", "estimate", "target", "outlook", "guidance" and other similar expressions within the meaning of securities laws of applicable jurisdictions. Actual values, results or events may be materially different to those expressed or implied in this presentation depending on a range of factors. Given these uncertainties, recipients are cautioned not to place reliance on forward-looking statements. No representation or warranty (express or implied) is made by Next Science or any of its directors, officers, employees, advisers or agents that any forecasts, projections, intentions, expectations or plans set out in this presentation will be achieved. Investors should form their own views as to these matters and any assumptions on which any of the forward looking statements are based and not place reliance on such statements.

An investment in the securities in Next Science is subject to known and unknown risks, many of which are beyond the control of Next Science, including factors and risks specific to the industry in which Next Science operates as well as general economic conditions, prevailing exchange rates and interest rates and conditions in the financial markets. Next Science does not guarantee any particular rate of return or the performance of Next Science, nor does it guarantee any particular tax treatment.

Before making an investment decision, investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs, and seek legal, taxation and financial advice appropriate to their jurisdiction and circumstances. Next Science is not licensed to provide financial product advice in respect of Next Science securities or any other financial products. Any references to or explanations of legislation, regulatory issues, benefits or any other legal commentary (if any) are indicative only, do not summarise all relevant issues and are not intended to be a full explanation of a particular matter.

To the maximum extent permitted by law, neither Next Science, nor any of its officers, directors, employees, agents and advisers, nor any other person, accepts any responsibility or liability for the content, accuracy or completeness of this presentation including, without limitation, any liability arising from fault or negligence, for any loss arising from the use of or reliance on any of the information contained in this presentation or otherwise arising in connection with it. In particular, but without prejudice to the generality of the foregoing, no representation, warranty or assurance is given as to the achievement or reasonableness of any future projections, management projections, management estimates or prospects contained in this presentation. This disclaimer also extends to all and any information and opinions contained in, and any omissions from, any other written or oral communications transmitted or otherwise made available to the recipient in connection with this presentation.

The distribution of this presentation to persons or in jurisdictions outside Australia may be restricted by law and any person into whose possession this document comes should seek advice on and observe those restrictions. Any failure to comply with such restrictions may violate applicable securities law.

To the maximum extent permitted by law, Next Science and its directors, officers, employees, advisers, agents and intermediaries disclaim any obligation or undertaking to release any updates or revisions to information to reflect any change in any of the information contained in this presentation (including, but not limited to, any assumptions or expectations set out in the presentation).

CEO messages

“Our purpose at Next Science is to heal patients and save lives by addressing the impacts of biofilms on human health, and to commercialise our Xbio technology platform for shareholders. We have a unique opportunity to change the trajectory of the war on infection by providing solutions that eliminate biofilms.


2019 was a year of achievements and learnings – we listed on the ASX in April raising A\$35m to fund our product development and growth and we launched two new products to market. We also learnt many lessons about bringing disruptive technologies to market including partnership management, proving our product value and continuing to develop clinical support with key opinion leaders.

We enter 2020 with momentum. Our focus is to continue to grow our revenue through a range of commercial efforts with several distribution and partnership models. We will launch 5 new products through the year while continuing to expand our patent and regulatory approval portfolios and build further clinical support for our products.”

The Science


“80% of infections in humans are in a biofilm” (CDC 2011)

The Solution – Xbio™ Technology



Deconstruct the bacterial biofilm barrier

Next Science's Xbio technology breaks the ionic bonds that hold the biofilm together. The polymers are then pulled into solution, effectively dissolving the biofilm barrier.



Destroy the bacteria within, through cell lysis¹

With the barrier dissolved, bacteria are exposed and more vulnerable to attack. Bacteria enveloped by Xbio technology experience cell lysis and are destroyed.

Cell lysis is non-discriminatory destroying gram-positive and gram-negative bacteria, persister cells, and spores. There is no known resistance mechanism to cell lysis.



Defend from recolonisation

The periodic release of bacteria from biofilms has been linked to chronic relapsing infections.² Disrupting and destroying the biofilm barrier can reduce the rate of biofilm recurrence by up to 1,000 times, effectively defending against recolonization.³ Unlike other agents that claim to destroy biofilms, there is no known evidence of bacterial resistance to the Xbio technology.

Xbio™ is the only non-toxic solution to deconstruct the bacteria's protective barrier. We've applied material science innovation to physically deconstruct the bacteria's protective structures, exposing and then eradicating bacteria through cell lysis¹, rather than using toxic or resistance building ingredients.

1. Lysis: disintegration by rupturing the cell membrane. 2. Costerton JW et al.


3. Potera C: antibiotic resistance: biofilm dispersing agent rejuvenates older antibiotics" Environmental Health Perspectives 118 (7) 228.

The opportunities

Biofilms pose a far-reaching threat to humans, animals and the environment

DEVICE-RELATED INFECTIONS

- 1) Ventricular derivations
- 2) Contact lens
- 3) Mouthwash
- 4) Endotracheal tubes
- 5) Vascular central catheters
- 6) Tissue fillers, breast implants
- 7) Peripheral vascular catheters
- 8) Prosthetic cardiac valves, pacemakers and vascular grafts
- 9) Urinary catheters
- 10) Orthopedic implants and prosthetic joints




TISSUE INFECTIONS

- 11) Acne
- 12) Chronic otitis media, chronic sinusitis
- 13) Chronic tonsillitis, dental plaque, chronic laryngitis
- 14) Endocarditis
- 15) Lung infection in cystic fibrosis
- 16) Kidney stones
- 17) Biliary tract infection
- 18) Urinary tract infection
- 19) Vaginosis
- 20) Osteomyelitis
- 21) Surgical site infections
- 22) Chronic wounds





- Products developed and/or available
- In development
- Active Research Underway
- No research at this time

Our Journey so far: a disruptive technology building market acceptance and growing revenues while creating new standards of care




“Helping patients daily while broadening and strengthening our patent portfolio to support our revenue growth ambitions”
J Mitchell Managing Director

Current Products in market generating revenues

Product	Commercial Pathway	Application	Total addressable market
Bactisure Surgical Lavage 	Global Distribution through Zimmer Biomet	Treatment of infected surgical cavities & implants	500,000 – 1 Million patients globally annually
BlastX Antimicrobial Wound Gel 	Global Distribution 3M KCI Advanced Wound Care	Treatment of chronic wounds: Foot & Leg Ulcers, Bedsores and Pressure Ulcers	10 Million patients globally 6 million patients (US only) annually
SurgX Sterile antimicrobial wound gel 	NXS distribution network in the US	Prevention of infection in surgical incisions. Used in the Operating room	58 Million procedures in the US annually
Acne Gel and cream 	Contract Manufacturer for Advanced Skin Technologies in Australia	Topical treatment of acne	Australian clinic market (1500) affiliated clinics



2020 plan: launch 5 new products, build clinical evidence, grow revenues

- Expand product portfolio to address infection prevention
- Focus on larger market opportunities to increase potential revenue, supported by level one clinical evidence





With a total global addressable market in excess of USD15 billion pa, XPerience Surgical Rinse represents a very high value opportunity for Next Science

2020 Pipeline of new product launches

Product	Target Launch	Commercial Pathway	Application	Total addressable market
XPerience Surgical Rinse 	2H 2020	NXS distribution network in the US Distribution partners outside the US	Intraoperative wash and last rinse in any surgical procedure	110 Million surgical procedures globally
TorrentX Wound Wash 	2H 2020	Partnered with Triad Life Sciences with the launch of their new tissue substitute product	Topical wash for treatment of chronic wounds: foot & leg ulcers in preparation for a tissue substitute	470,000 procedures in the US annually
Non Salicylic Acid Acne Cream & Cleanser	March 2020	tbh skin care (ANZ) (Online marketing company)	Topical treatment of acne	Target audience 1.5 Million female teenagers in Australia.

2020 Pipeline of new product launches

Product	Target Launch Date	Commercial Pathway	Application	Total addressable market
Middle Ear Wash 	Q1 2021	Under Negotiation	Chronic middle ear infection being treated with tympanoplasty	3 Million surgeries in the US per annum
RipRecovery Hand Repair 	May 2020	Direct Online marketing in the US	Skin Repair cream for Elite Athletes	4 Million cross fit devotees globally
Biofilm effective Disinfectant for Hard Surfaces	H2 2020	Under Negotiation	Walls, floors, hospital furniture and fittings	Global surface disinfectant market \$600 Million annually

Medium Term New Product Pipeline

Product	Application	Total addressable market	Market Ready
Sinus Wash (Medical device)	Treatment of chronic sinusitis during FESS surgeries and balloon sinuplasty	US: 1 million procedures per annum	2021
Nasal stent (Medical Device)	Anti microbial packing stent for recovery from nasal surgery and also an antimicrobial barrier to protect against infection during the recovery period	US: 500,000 surgeries per annum (ENT, Sinus & Rhinoplasty)	2022
Adhesion barrier (Medical Device)	Provides separation between organs as they heal, stopping adhesions which are known to cause complications and pain post abdominal surgery	Global Market currently \$800 M USD	2023
Topical treatment of Skin Cancer (AKs, sBCCs) (Drug)	Treatment of early skin cancers through a topical drug, with no side effects	sBCCs: 5.4M cancers annually in the US Actinic Keratosis: Averages about 18% of total US adult population	2023-4
Coatings for implants (Medical Device)	Soft coatings to provide medical devices with antimicrobial coverage	+3 Million Orthopaedic implants 1.6 Million Cardiac Devices	2024

Current Distribution Partners

Product	Distribution	Market	Coverage	Comment
Bactisure Surgical Lavage	Zimmer Biomet Global Partner	Use in the sterile field (surgery), generally marketed to joint replacement surgeons to treat Prosthetic Joint Infection	Direct Sales representatives and Contract Sales representatives (US 2000)	Started in 2017, steady build up (50% growth) year on year.
BlastX Antimicrobial Wound Gel	3M KCI Global Partner	Topical Treatment of Chronic wounds DFU, VLU, pressure sores	US KCI Advanced Wound care team (AWD) and 3M After care team – 120 people	Launched with KCI AWD team in January 2020
SurgX Sterile Antimicrobial Wound Gel (prevention of Surgical site infection)	Next Science Direct Distribution Network	Topical prevention of surgical site infection, suitable for use on all skin level sutures	Independent sales representatives managed by Next Science sales management team. Target sales force for XPerience launch; 250 representatives	Currently training 95 independent sales representatives. Expect to see positive benefits in H2 2020

NXS Key Topics

Topic	NXS View
What do trial results and other evidence say about the efficacy of NXS products?	<ul style="list-style-type: none"> • All trials across all products have shown superior performance to current standards of care • Increased key opinion leader support for our technology to communicate product superiority and clinical efficacy • In 2020 further investment in larger level one randomised controlled trials are taking place to provide a greater body of evidence to drive market adoption.
How would you describe your 2019 results?	<ul style="list-style-type: none"> • After a positive first half, sales in H2 were negatively impacted by M&A activity by 3M and industry wide regulatory delays in Europe. • Very pleased with the product development portfolio creating the base for 5 new product launches in 2020. Broader distribution strategy with independent sales representation to drive additional revenue streams.
What is your outlook for European regulatory approvals?	<ul style="list-style-type: none"> • We have products in progress for CE Mark. Bactisure is likely to be cleared in Q2, and we are still waiting for clarity on the position of BlastX, as the regulation in Europe moves to the Medical Device Regulation (MDR).

NXS Key Topics

Topic	NXS View
How effective is your distribution strategy?	<ul style="list-style-type: none">• In 2020 we are supplementing our distribution strategy with new pathways and additional partners to improve market penetration and revenue growth:<ul style="list-style-type: none">• Two products will go direct to consumer through online direct marketing (Acne and Skin repair)• The 3rd party Surgical Sales network of independent sales representatives will carry the Infection Prevention products that target the surgical market. Current size of this network is 95 people, expanding to 250 to support the launch of XPerience Surgical Rinse
What are the benchmarks for success for 2020?	<ul style="list-style-type: none">• Improve the revenue growth trajectory• Launch 5 new products on time• 9 in market in 2020• Continue development of new partners with new products
What does long term success look like for NXS?	<ul style="list-style-type: none">• NXS products established as part of standard of care protocols in many of today's standard medical procedures that happen in thousands of hospitals and clinics around the world every day. This will provide the foundation for a large successful multinational medical products enterprise

Profit and loss (underlying)

Year ended 31 Dec USD\$('000)	2018	2019	Variance
Revenue	2,844	4,061	43%
Cost of Sales	(370)	(550)	
Gross Profit	2,474	3,511	42%
Other Income	-	35	
Research & Development ²	(1,242)	(1,732)	39%
Employee Expenses	(10,061)	(7,906)	(21%)
Sales & Marketing	(472)	(602)	28%
Consultancy & Regulatory	(1,298)	(1,686)	30%
General and Administration	(2,504)	(2,744)	10%
Operating Expenses	(15,577)	(14,635)	
EBITDA (Underlying) ¹	(13,103)	(11,124)	
Gross Margin	87%	86%	

- ▶ Revenue increased by 43% vs prior comparative period (pcp).
- ▶ Revenue growth trajectory in 2019 was temporarily constrained by 3M's acquisition of Acclivity Inc (and its KCI subsidiaries) and European regulatory delays.
- ▶ Increased R&D spend – focus on extending claims on existing products as well as new products such as Middle Ear, Sinus Wash and Surgical Rinse.
- ▶ Sales & Marketing costs up 28% - customer education and training programs for existing and newly release products (Acne), including webinar and webcast developments related to wound care and biofilms.
- ▶ Employee expenses down by 21% - reflects sales and marketing restructure in December 2018. 9 direct sales staff remain to support partner activity and to advance sales of direct to consumer products. Additional headcount in 2019 includes 5 staff in R&D and 3 across regulatory, quality and operations.
- ▶ Consultancy & regulatory costs up 30% - includes spend incurred in relation to CE Mark approvals and additional compliance costs of being a listed entity.

1. 2018 & 2019 EBITDA have been adjusted to exclude IPO and other one-off costs. Refer to Appendix 1 & 2 for reconciliations. FY2019 includes IFRS 16 accounting for leases.


2. R & D expenses are external costs for testing and validation and do not include any internal Employee costs.

Balance sheet

Year ended 31 Dec USD\$('000)	2018	2019
Cash and cash equivalents	7,211	16,910
Property, plant and equipment	639	813
Intangible assets	1,183	2,164
Other assets	1,597	2,812
Total assets	10,630	22,699
Loans and borrowings	(7,069)	-
Other liabilities	(3,157)	(3,336)
Total liabilities	(10,226)	(3,336)
Net assets	404	19,363
Share Capital ²	56,589	90,694
Reserves	(41,439)	(42,147)
Accumulated losses ²	(14,746)	(29,184)
Total Equity	404	19,363


- ▶ \$16.9m in cash at 31 Dec 2019 to fund our business plan and grow investments.
- ▶ \$25m (AUD\$35m) was raised during the IPO in April 2019. Proceeds were converted to USD in Q2 2019.
- ▶ \$7m of Converting Notes issued in 2018 were converted to shares upon IPO in April 2019. No remaining interest bearing debt.
- ▶ Intangible assets include \$1m of R&D costs capitalised during 2019 bringing total R&D spend in 2019 to \$2.7m (2018: \$1.6m). Increase in R&D spend of 69% in 2019.

	Statutory FY 18	Statutory FY 19
R&D spend as a % of revenue ¹	57%	66%



1. R&D spend includes the income statement expense and capitalised costs in the reference period
2. Included within Share capital and Accumulated losses is US\$1.8m relating to notional interest on the converting note where the accounting treatment has changed since the half-year to reflect that the convertible note includes an embedded derivative on inception that is required to be expensed through profit and loss over the period until conversion in April 2019.

Cash flow waterfall (\$USm)



- ▶ Total net cash receipts for the year of \$27.4m
- ▶ Year end bank balance of \$16.9m

Outlook and key milestones

Grow sales revenue in 2020:

- **Grow existing product revenues:**

- Continued focus with partners on existing products including geographic market expansion when appropriate regulatory approvals are cleared and the launch of BlastX with the 3M KCI sales force Q1 2020

- **Expand distribution**

- Build out of independent sales distributor network for surgery products (SurgX & Xperience) in the US Q1-Q3 2020

- **New partners and 5 new product launches**

- tbh Skin Care Acne Cream & Wash Q1 2020
- RIPRecovery Skin repair cream Q2 2020
- XPerience Surgical Rinse H2 2020
- TorrentX Wound Wash and wound bed preparation H2 2020

Outlook and key milestones

Building evidence and approvals

- Randomised Controlled Trials to showcase the performance of Preventative products (SurgX and Xperience)
- Advance submissions with FDA for approval to commence Phase II and Phase III clinical trials in topical skin cancer by Q1 2021
- Approval of hard surface disinfectant with Biofilm eradication claim from the EPA
- Continued expansion of patent portfolio and industry partnerships to support product commercialisation

Milestone dates

Q2 2020 – Q4 2021

Q4 2020

Q3 2020

Appendix 1

Reconciliation: 2019 Statutory to Underlying EBITDA

In USD \$'(000)	Statutory results per FY19 financial statements	IPO costs	Converting note broker fees	Underlying results
Year ended 31 December 2019				
Revenue	4,061	-	-	4,061
Cost of sales	(550)	-	-	(550)
Gross profit	3,511	-	-	3,511
Other income	35	-	-	35
Research and development	(1,732)	-	-	(1,732)
Employee expenses	(7,906)	-	-	(7,906)
Sales and marketing	(650)	48	-	(602)
Consultancy and regulatory	(2,138)	178	274	(1,686)
General and administration	(3,056)	312	-	(2,744)
EBITDA	(11,936)	538	274	(11,124)

Appendix 2

Reconciliation: 2018 Statutory to Underlying EBITDA

In USD \$'(000)	Statutory results per FY18 financial statements	IPO costs	Converting note broker fees	Redundancy costs – Sales & Marketing restructure	Underlying results
Year ended 31 December 2018					
Revenue	2,844	-	-	-	2,844
Cost of sales	(370)	-	-	-	(370)
Gross profit	2,474	-	-		2,474
Research and development	(1,242)	-	-	-	(1,242)
Employee expenses	(10,380)	-	-	319	(10,061)
Sales and marketing	(499)	27	-	-	(472)
Consultancy and regulatory	(1,401)	76	27	-	(1,298)
General and administration	(2,522)	18	-	-	(2,504)
EBITDA	(13,570)	121	27	319	(13,103)

Appendix 3

Corporate Overview

Stock Overview

ASX code	NXS
Share Price (Feb 27, 2020)	\$1.84
Market capitalisation @ \$2.08	\$376m
Total Shares on Issue	180.7m
Listed Shares (tradable)	68.0m
Escrowed Shares	112.7m
Options	9.2m
Shareholders (1,555 at listing)	5,035
Average daily volume (since listing)	458k shares


Substantial Shareholders

Auckland Trust Company Ltd*	25.74%
Walker Group Holdings Pty Ltd*	16.05%
Matthew Mynnti (Founder & CTO)	11.43%
Judith Mitchell (Managing Director)	2.62%
Total Board & Management Shareholdings	14.50%

* Entities related to Lang Walker including disclosed purchases

Number of Escrowed Securities

Shares escrowed until 18 April 2020	39.85m
Shares escrowed until 18 April 2021	72.85m
Total Shares Escrowed	112.7m
Options escrowed until 18 April 2021	5.85m



Appendix 4

XPerience product data


XPerience Surgical Wash is packaged as a sterile solution in a 500mL Polypropylene bag. The solution is designed to be attached to common delivery systems used in the Operating room via a spike port. The solution is then used to irrigate the surgery site.

Competitive Advantages:


- Able to be left in the surgical cavity post rinse (Betadine & Irrisept need to be rinsed out of the cavity as per product labelling for use)
- Exceptionally effective against all known pathogens
 - MRSA
 - Pseudomonas
 - Candida fungi
 - C.acne
 - E.coli
 - S. epidermis
- Active for > 3 hours



Sustained Activity



Comparison of Surgical Lavage Solutions - MSU Drip Flow Testing (72 hour biofilm)



Appendix 5


NXS Acne Cream - tbh Skincare



- Direct distribution to consumer via online website only
- Website live from 18th March 2020
- Landing page to capture active interest in product currently live at <https://tbhskincare.com/>
- Individual sample group conducted with 20 females
- Social media and influencer paid marketing to launch product across Instagram, Facebook & YouTube



the biofilm hack



LAUNCHING
18 March
2020



@tbhskincare_
16 yr old female, result after 7 weeks

“

A lot of the time I would not go to school or even out of the house because of how gross and ugly I felt.

I am absolutely obsessed with my skin. And I have noticed I am so much happier!

NEXT SCIENCE®

Break through biofilm.

JUDITH MITCHELL MANAGING DIRECTOR

Suite 1902, Zenith Centre 821 Pacific Highway Chatswood NSW 2067

investorqueries@nextscience.com | +61 2 8607 5125 | NextScience.com

Additional biofilm education can be found at: biofilm.healthcare